CN111603556A - 一种新型冠状病毒亚单位纳米疫苗的制备和应用 - Google Patents
一种新型冠状病毒亚单位纳米疫苗的制备和应用 Download PDFInfo
- Publication number
- CN111603556A CN111603556A CN202010336985.0A CN202010336985A CN111603556A CN 111603556 A CN111603556 A CN 111603556A CN 202010336985 A CN202010336985 A CN 202010336985A CN 111603556 A CN111603556 A CN 111603556A
- Authority
- CN
- China
- Prior art keywords
- cpg
- lipid
- solution containing
- protein
- cov
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 229960005486 vaccine Drugs 0.000 title claims abstract description 20
- 241000711573 Coronaviridae Species 0.000 title abstract description 10
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 claims abstract description 95
- 239000002105 nanoparticle Substances 0.000 claims abstract description 74
- 239000002671 adjuvant Substances 0.000 claims abstract description 55
- 150000002632 lipids Chemical class 0.000 claims abstract description 43
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 37
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 36
- -1 cationic lipid Chemical class 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 14
- 230000008569 process Effects 0.000 claims abstract description 10
- 241001678559 COVID-19 virus Species 0.000 claims abstract description 9
- 208000025721 COVID-19 Diseases 0.000 claims abstract description 4
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 claims description 45
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 40
- 239000002245 particle Substances 0.000 claims description 31
- 108091005609 SARS-CoV-2 Spike Subunit S1 Proteins 0.000 claims description 28
- 239000002502 liposome Substances 0.000 claims description 28
- 239000012528 membrane Substances 0.000 claims description 21
- KYHYBIADZPAZKE-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;bromide Chemical compound [Br-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KYHYBIADZPAZKE-LQDDAWAPSA-M 0.000 claims description 20
- 235000012000 cholesterol Nutrition 0.000 claims description 20
- 238000002156 mixing Methods 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 239000000568 immunological adjuvant Substances 0.000 claims description 12
- 238000009210 therapy by ultrasound Methods 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 8
- 238000004108 freeze drying Methods 0.000 claims description 6
- 239000008367 deionised water Substances 0.000 claims description 5
- 229910021641 deionized water Inorganic materials 0.000 claims description 5
- 230000002163 immunogen Effects 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 4
- 230000001571 immunoadjuvant effect Effects 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 208000037847 SARS-CoV-2-infection Diseases 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 abstract description 17
- 229910052782 aluminium Inorganic materials 0.000 abstract description 17
- 239000000427 antigen Substances 0.000 abstract description 16
- 102000036639 antigens Human genes 0.000 abstract description 16
- 108091007433 antigens Proteins 0.000 abstract description 16
- 230000004727 humoral immunity Effects 0.000 abstract description 5
- 241001465754 Metazoa Species 0.000 abstract description 4
- 230000007969 cellular immunity Effects 0.000 abstract description 4
- 238000002474 experimental method Methods 0.000 abstract description 3
- 230000003213 activating effect Effects 0.000 abstract 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 45
- 241000699670 Mus sp. Species 0.000 description 34
- 230000003053 immunization Effects 0.000 description 27
- 101001028244 Onchocerca volvulus Fatty-acid and retinol-binding protein 1 Proteins 0.000 description 26
- 239000000243 solution Substances 0.000 description 26
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 25
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 24
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 24
- 238000002649 immunization Methods 0.000 description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- 210000002966 serum Anatomy 0.000 description 14
- 210000001744 T-lymphocyte Anatomy 0.000 description 12
- 108010002350 Interleukin-2 Proteins 0.000 description 9
- 241000700605 Viruses Species 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 230000001900 immune effect Effects 0.000 description 8
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 7
- 238000001514 detection method Methods 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 5
- 238000002390 rotary evaporation Methods 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- 102100037850 Interferon gamma Human genes 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 108010089804 glycyl-threonine Proteins 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 description 3
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 3
- 108010057821 leucylproline Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 108010061238 threonyl-glycine Proteins 0.000 description 3
- XMIAMUXIMWREBJ-HERUPUMHSA-N Ala-Trp-Asn Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(=O)N)C(=O)O)N XMIAMUXIMWREBJ-HERUPUMHSA-N 0.000 description 2
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 2
- 102100031673 Corneodesmosin Human genes 0.000 description 2
- 101710139375 Corneodesmosin Proteins 0.000 description 2
- 101710091045 Envelope protein Proteins 0.000 description 2
- IZVICCORZOSGPT-JSGCOSHPSA-N Gly-Val-Tyr Chemical compound [H]NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O IZVICCORZOSGPT-JSGCOSHPSA-N 0.000 description 2
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 241000880493 Leptailurus serval Species 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 2
- 108010079364 N-glycylalanine Proteins 0.000 description 2
- 102000011931 Nucleoproteins Human genes 0.000 description 2
- 108010061100 Nucleoproteins Proteins 0.000 description 2
- XYHMFGGWNOFUOU-QXEWZRGKSA-N Pro-Ile-Gly Chemical compound OC(=O)CNC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]1CCCN1 XYHMFGGWNOFUOU-QXEWZRGKSA-N 0.000 description 2
- 229940096437 Protein S Drugs 0.000 description 2
- 101710188315 Protein X Proteins 0.000 description 2
- 241000315672 SARS coronavirus Species 0.000 description 2
- TYYBJUYSTWJHGO-ZKWXMUAHSA-N Ser-Asn-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O TYYBJUYSTWJHGO-ZKWXMUAHSA-N 0.000 description 2
- 101710198474 Spike protein Proteins 0.000 description 2
- 102100021696 Syncytin-1 Human genes 0.000 description 2
- UTSWGQNAQRIHAI-UNQGMJICSA-N Thr-Arg-Phe Chemical compound NC(N)=NCCC[C@H](NC(=O)[C@@H](N)[C@H](O)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 UTSWGQNAQRIHAI-UNQGMJICSA-N 0.000 description 2
- PZVGOVRNGKEFCB-KKHAAJSZSA-N Thr-Asn-Val Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)O)N)O PZVGOVRNGKEFCB-KKHAAJSZSA-N 0.000 description 2
- ONNSECRQFSTMCC-XKBZYTNZSA-N Thr-Glu-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O ONNSECRQFSTMCC-XKBZYTNZSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 108010069495 cysteinyltyrosine Proteins 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002296 dynamic light scattering Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 description 2
- 108010087823 glycyltyrosine Proteins 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000010287 polarization Effects 0.000 description 2
- 108010029020 prolylglycine Proteins 0.000 description 2
- 229940023143 protein vaccine Drugs 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- UGLPMYSCWHTZQU-AUTRQRHGSA-N Ala-Ala-Tyr Chemical compound C[C@H]([NH3+])C(=O)N[C@@H](C)C(=O)N[C@H](C([O-])=O)CC1=CC=C(O)C=C1 UGLPMYSCWHTZQU-AUTRQRHGSA-N 0.000 description 1
- ODWSTKXGQGYHSH-FXQIFTODSA-N Ala-Arg-Ala Chemical compound C[C@H](N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O ODWSTKXGQGYHSH-FXQIFTODSA-N 0.000 description 1
- LBJYAILUMSUTAM-ZLUOBGJFSA-N Ala-Asn-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O LBJYAILUMSUTAM-ZLUOBGJFSA-N 0.000 description 1
- KUDREHRZRIVKHS-UWJYBYFXSA-N Ala-Asp-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O KUDREHRZRIVKHS-UWJYBYFXSA-N 0.000 description 1
- BVSGPHDECMJBDE-HGNGGELXSA-N Ala-Glu-His Chemical compound C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N BVSGPHDECMJBDE-HGNGGELXSA-N 0.000 description 1
- LMFXXZPPZDCPTA-ZKWXMUAHSA-N Ala-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N LMFXXZPPZDCPTA-ZKWXMUAHSA-N 0.000 description 1
- NMXKFWOEASXOGB-QSFUFRPTSA-N Ala-Ile-His Chemical compound C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 NMXKFWOEASXOGB-QSFUFRPTSA-N 0.000 description 1
- DPNZTBKGAUAZQU-DLOVCJGASA-N Ala-Leu-His Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N DPNZTBKGAUAZQU-DLOVCJGASA-N 0.000 description 1
- SYIFFFHSXBNPMC-UWJYBYFXSA-N Ala-Ser-Tyr Chemical compound C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N SYIFFFHSXBNPMC-UWJYBYFXSA-N 0.000 description 1
- ARHJJAAWNWOACN-FXQIFTODSA-N Ala-Ser-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O ARHJJAAWNWOACN-FXQIFTODSA-N 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- KWKQGHSSNHPGOW-BQBZGAKWSA-N Arg-Ala-Gly Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)NCC(O)=O KWKQGHSSNHPGOW-BQBZGAKWSA-N 0.000 description 1
- OTCJMMRQBVDQRK-DCAQKATOSA-N Arg-Asp-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O OTCJMMRQBVDQRK-DCAQKATOSA-N 0.000 description 1
- MFAMTAVAFBPXDC-LPEHRKFASA-N Arg-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O MFAMTAVAFBPXDC-LPEHRKFASA-N 0.000 description 1
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 1
- VRZDJJWOFXMFRO-ZFWWWQNUSA-N Arg-Gly-Trp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O VRZDJJWOFXMFRO-ZFWWWQNUSA-N 0.000 description 1
- FSNVAJOPUDVQAR-AVGNSLFASA-N Arg-Lys-Arg Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O FSNVAJOPUDVQAR-AVGNSLFASA-N 0.000 description 1
- FRBAHXABMQXSJQ-FXQIFTODSA-N Arg-Ser-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O FRBAHXABMQXSJQ-FXQIFTODSA-N 0.000 description 1
- BECXEHHOZNFFFX-IHRRRGAJSA-N Arg-Ser-Tyr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O BECXEHHOZNFFFX-IHRRRGAJSA-N 0.000 description 1
- ZZXMOQIUIJJOKZ-ZLUOBGJFSA-N Asn-Asn-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC(N)=O ZZXMOQIUIJJOKZ-ZLUOBGJFSA-N 0.000 description 1
- ZDOQDYFZNGASEY-BIIVOSGPSA-N Asn-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)N)N)C(=O)O ZDOQDYFZNGASEY-BIIVOSGPSA-N 0.000 description 1
- HYQYLOSCICEYTR-YUMQZZPRSA-N Asn-Gly-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O HYQYLOSCICEYTR-YUMQZZPRSA-N 0.000 description 1
- YYSYDIYQTUPNQQ-SXTJYALSSA-N Asn-Ile-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O YYSYDIYQTUPNQQ-SXTJYALSSA-N 0.000 description 1
- NLRJGXZWTKXRHP-DCAQKATOSA-N Asn-Leu-Arg Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O NLRJGXZWTKXRHP-DCAQKATOSA-N 0.000 description 1
- NCFJQJRLQJEECD-NHCYSSNCSA-N Asn-Leu-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O NCFJQJRLQJEECD-NHCYSSNCSA-N 0.000 description 1
- ZYPWIUFLYMQZBS-SRVKXCTJSA-N Asn-Lys-Lys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N ZYPWIUFLYMQZBS-SRVKXCTJSA-N 0.000 description 1
- RTFWCVDISAMGEQ-SRVKXCTJSA-N Asn-Phe-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N RTFWCVDISAMGEQ-SRVKXCTJSA-N 0.000 description 1
- RVHGJNGNKGDCPX-KKUMJFAQSA-N Asn-Phe-Lys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N RVHGJNGNKGDCPX-KKUMJFAQSA-N 0.000 description 1
- RTFXPCYMDYBZNQ-SRVKXCTJSA-N Asn-Tyr-Asn Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(O)=O RTFXPCYMDYBZNQ-SRVKXCTJSA-N 0.000 description 1
- QNNBHTFDFFFHGC-KKUMJFAQSA-N Asn-Tyr-Lys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N)O QNNBHTFDFFFHGC-KKUMJFAQSA-N 0.000 description 1
- UGIBTKGQVWFTGX-BIIVOSGPSA-N Asp-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)N)C(=O)O UGIBTKGQVWFTGX-BIIVOSGPSA-N 0.000 description 1
- HRGGPWBIMIQANI-GUBZILKMSA-N Asp-Gln-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O HRGGPWBIMIQANI-GUBZILKMSA-N 0.000 description 1
- PGUYEUCYVNZGGV-QWRGUYRKSA-N Asp-Gly-Tyr Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 PGUYEUCYVNZGGV-QWRGUYRKSA-N 0.000 description 1
- KLYPOCBLKMPBIQ-GHCJXIJMSA-N Asp-Ile-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC(=O)O)N KLYPOCBLKMPBIQ-GHCJXIJMSA-N 0.000 description 1
- SPWXXPFDTMYTRI-IUKAMOBKSA-N Asp-Ile-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SPWXXPFDTMYTRI-IUKAMOBKSA-N 0.000 description 1
- USNJAPJZSGTTPX-XVSYOHENSA-N Asp-Phe-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O USNJAPJZSGTTPX-XVSYOHENSA-N 0.000 description 1
- CZIVKMOEXPILDK-SRVKXCTJSA-N Asp-Tyr-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O CZIVKMOEXPILDK-SRVKXCTJSA-N 0.000 description 1
- OIMUAKUQOUEPCZ-WHFBIAKZSA-N Cys-Asn-Gly Chemical compound SC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O OIMUAKUQOUEPCZ-WHFBIAKZSA-N 0.000 description 1
- WDQXKVCQXRNOSI-GHCJXIJMSA-N Cys-Asp-Ile Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WDQXKVCQXRNOSI-GHCJXIJMSA-N 0.000 description 1
- UYYZZJXUVIZTMH-AVGNSLFASA-N Cys-Glu-Phe Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O UYYZZJXUVIZTMH-AVGNSLFASA-N 0.000 description 1
- VPQZSNQICFCCSO-BJDJZHNGSA-N Cys-Leu-Ile Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VPQZSNQICFCCSO-BJDJZHNGSA-N 0.000 description 1
- CNAMJJOZGXPDHW-IHRRRGAJSA-N Cys-Pro-Phe Chemical compound N[C@@H](CS)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(O)=O CNAMJJOZGXPDHW-IHRRRGAJSA-N 0.000 description 1
- FCXJJTRGVAZDER-FXQIFTODSA-N Cys-Val-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O FCXJJTRGVAZDER-FXQIFTODSA-N 0.000 description 1
- NGOIQDYZMIKCOK-NAKRPEOUSA-N Cys-Val-Ile Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O NGOIQDYZMIKCOK-NAKRPEOUSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- LVNILKSSFHCSJZ-IHRRRGAJSA-N Gln-Gln-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)N)N LVNILKSSFHCSJZ-IHRRRGAJSA-N 0.000 description 1
- HDUDGCZEOZEFOA-KBIXCLLPSA-N Gln-Ile-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)O)NC(=O)[C@H](CCC(=O)N)N HDUDGCZEOZEFOA-KBIXCLLPSA-N 0.000 description 1
- DSRVQBZAMPGEKU-AVGNSLFASA-N Gln-Phe-Cys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCC(=O)N)N DSRVQBZAMPGEKU-AVGNSLFASA-N 0.000 description 1
- MQJDLNRXBOELJW-KKUMJFAQSA-N Gln-Pro-Phe Chemical compound N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(O)=O MQJDLNRXBOELJW-KKUMJFAQSA-N 0.000 description 1
- LPIKVBWNNVFHCQ-GUBZILKMSA-N Gln-Ser-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O LPIKVBWNNVFHCQ-GUBZILKMSA-N 0.000 description 1
- YRHZWVKUFWCEPW-GLLZPBPUSA-N Gln-Thr-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)N)N)O YRHZWVKUFWCEPW-GLLZPBPUSA-N 0.000 description 1
- NHMRJKKAVMENKJ-WDCWCFNPSA-N Gln-Thr-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O NHMRJKKAVMENKJ-WDCWCFNPSA-N 0.000 description 1
- CKRUHITYRFNUKW-WDSKDSINSA-N Glu-Asn-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O CKRUHITYRFNUKW-WDSKDSINSA-N 0.000 description 1
- QXDXIXFSFHUYAX-MNXVOIDGSA-N Glu-Ile-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCC(O)=O QXDXIXFSFHUYAX-MNXVOIDGSA-N 0.000 description 1
- RBXSZQRSEGYDFG-GUBZILKMSA-N Glu-Lys-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O RBXSZQRSEGYDFG-GUBZILKMSA-N 0.000 description 1
- KJBGAZSLZAQDPV-KKUMJFAQSA-N Glu-Phe-Arg Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)N KJBGAZSLZAQDPV-KKUMJFAQSA-N 0.000 description 1
- SYWCGQOIIARSIX-SRVKXCTJSA-N Glu-Pro-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O SYWCGQOIIARSIX-SRVKXCTJSA-N 0.000 description 1
- MLILEEIVMRUYBX-NHCYSSNCSA-N Glu-Val-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O MLILEEIVMRUYBX-NHCYSSNCSA-N 0.000 description 1
- CLODWIOAKCSBAN-BQBZGAKWSA-N Gly-Arg-Asp Chemical compound NC(N)=NCCC[C@H](NC(=O)CN)C(=O)N[C@@H](CC(O)=O)C(O)=O CLODWIOAKCSBAN-BQBZGAKWSA-N 0.000 description 1
- LCNXZQROPKFGQK-WHFBIAKZSA-N Gly-Asp-Ser Chemical compound NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O LCNXZQROPKFGQK-WHFBIAKZSA-N 0.000 description 1
- JSNNHGHYGYMVCK-XVKPBYJWSA-N Gly-Glu-Val Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O JSNNHGHYGYMVCK-XVKPBYJWSA-N 0.000 description 1
- PTIIBFKSLCYQBO-NHCYSSNCSA-N Gly-Lys-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)CN PTIIBFKSLCYQBO-NHCYSSNCSA-N 0.000 description 1
- YYXJFBMCOUSYSF-RYUDHWBXSA-N Gly-Phe-Gln Chemical compound [H]NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O YYXJFBMCOUSYSF-RYUDHWBXSA-N 0.000 description 1
- LCRDMSSAKLTKBU-ZDLURKLDSA-N Gly-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CN LCRDMSSAKLTKBU-ZDLURKLDSA-N 0.000 description 1
- FKESCSGWBPUTPN-FOHZUACHSA-N Gly-Thr-Asn Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O FKESCSGWBPUTPN-FOHZUACHSA-N 0.000 description 1
- RYAOJUMWLWUGNW-QMMMGPOBSA-N Gly-Val-Gly Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O RYAOJUMWLWUGNW-QMMMGPOBSA-N 0.000 description 1
- BAYQNCWLXIDLHX-ONGXEEELSA-N Gly-Val-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)CN BAYQNCWLXIDLHX-ONGXEEELSA-N 0.000 description 1
- 241000711467 Human coronavirus 229E Species 0.000 description 1
- 241001109669 Human coronavirus HKU1 Species 0.000 description 1
- 241000482741 Human coronavirus NL63 Species 0.000 description 1
- 241001428935 Human coronavirus OC43 Species 0.000 description 1
- VSZALHITQINTGC-GHCJXIJMSA-N Ile-Ala-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)O)N VSZALHITQINTGC-GHCJXIJMSA-N 0.000 description 1
- YPQDTQJBOFOTJQ-SXTJYALSSA-N Ile-Asn-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N YPQDTQJBOFOTJQ-SXTJYALSSA-N 0.000 description 1
- JLWLMGADIQFKRD-QSFUFRPTSA-N Ile-His-Ala Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CC1=CN=CN1 JLWLMGADIQFKRD-QSFUFRPTSA-N 0.000 description 1
- UDBPXJNOEWDBDF-XUXIUFHCSA-N Ile-Lys-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)O)N UDBPXJNOEWDBDF-XUXIUFHCSA-N 0.000 description 1
- UAELWXJFLZBKQS-WHOFXGATSA-N Ile-Phe-Gly Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(O)=O UAELWXJFLZBKQS-WHOFXGATSA-N 0.000 description 1
- JODPUDMBQBIWCK-GHCJXIJMSA-N Ile-Ser-Asn Chemical compound [H]N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O JODPUDMBQBIWCK-GHCJXIJMSA-N 0.000 description 1
- SAEWJTCJQVZQNZ-IUKAMOBKSA-N Ile-Thr-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N SAEWJTCJQVZQNZ-IUKAMOBKSA-N 0.000 description 1
- ANTFEOSJMAUGIB-KNZXXDILSA-N Ile-Thr-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@@H]1C(=O)O)N ANTFEOSJMAUGIB-KNZXXDILSA-N 0.000 description 1
- IPFKIGNDTUOFAF-CYDGBPFRSA-N Ile-Val-Arg Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IPFKIGNDTUOFAF-CYDGBPFRSA-N 0.000 description 1
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 1
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 1
- VCSBGUACOYUIGD-CIUDSAMLSA-N Leu-Asn-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O VCSBGUACOYUIGD-CIUDSAMLSA-N 0.000 description 1
- MMEDVBWCMGRKKC-GARJFASQSA-N Leu-Asp-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N MMEDVBWCMGRKKC-GARJFASQSA-N 0.000 description 1
- PVMPDMIKUVNOBD-CIUDSAMLSA-N Leu-Asp-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O PVMPDMIKUVNOBD-CIUDSAMLSA-N 0.000 description 1
- YORLGJINWYYIMX-KKUMJFAQSA-N Leu-Cys-Phe Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O YORLGJINWYYIMX-KKUMJFAQSA-N 0.000 description 1
- GPICTNQYKHHHTH-GUBZILKMSA-N Leu-Gln-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O GPICTNQYKHHHTH-GUBZILKMSA-N 0.000 description 1
- NEEOBPIXKWSBRF-IUCAKERBSA-N Leu-Glu-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O NEEOBPIXKWSBRF-IUCAKERBSA-N 0.000 description 1
- PBGDOSARRIJMEV-DLOVCJGASA-N Leu-His-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C)C(O)=O PBGDOSARRIJMEV-DLOVCJGASA-N 0.000 description 1
- OYQUOLRTJHWVSQ-SRVKXCTJSA-N Leu-His-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(O)=O OYQUOLRTJHWVSQ-SRVKXCTJSA-N 0.000 description 1
- JKSIBWITFMQTOA-XUXIUFHCSA-N Leu-Ile-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O JKSIBWITFMQTOA-XUXIUFHCSA-N 0.000 description 1
- RTIRBWJPYJYTLO-MELADBBJSA-N Leu-Lys-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@@H]1C(=O)O)N RTIRBWJPYJYTLO-MELADBBJSA-N 0.000 description 1
- WXZOHBVPVKABQN-DCAQKATOSA-N Leu-Met-Asp Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)O)N WXZOHBVPVKABQN-DCAQKATOSA-N 0.000 description 1
- GCXGCIYIHXSKAY-ULQDDVLXSA-N Leu-Phe-Arg Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O GCXGCIYIHXSKAY-ULQDDVLXSA-N 0.000 description 1
- DRWMRVFCKKXHCH-BZSNNMDCSA-N Leu-Phe-Leu Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C([O-])=O)CC1=CC=CC=C1 DRWMRVFCKKXHCH-BZSNNMDCSA-N 0.000 description 1
- BMVFXOQHDQZAQU-DCAQKATOSA-N Leu-Pro-Asp Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(=O)O)C(=O)O)N BMVFXOQHDQZAQU-DCAQKATOSA-N 0.000 description 1
- XXXXOVFBXRERQL-ULQDDVLXSA-N Leu-Pro-Phe Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 XXXXOVFBXRERQL-ULQDDVLXSA-N 0.000 description 1
- JIHDFWWRYHSAQB-GUBZILKMSA-N Leu-Ser-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O JIHDFWWRYHSAQB-GUBZILKMSA-N 0.000 description 1
- KLSUAWUZBMAZCL-RHYQMDGZSA-N Leu-Thr-Pro Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(O)=O KLSUAWUZBMAZCL-RHYQMDGZSA-N 0.000 description 1
- WUHBLPVELFTPQK-KKUMJFAQSA-N Leu-Tyr-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(O)=O WUHBLPVELFTPQK-KKUMJFAQSA-N 0.000 description 1
- FBNPMTNBFFAMMH-UHFFFAOYSA-N Leu-Val-Arg Natural products CC(C)CC(N)C(=O)NC(C(C)C)C(=O)NC(C(O)=O)CCCN=C(N)N FBNPMTNBFFAMMH-UHFFFAOYSA-N 0.000 description 1
- ABHIXYDMILIUKV-CIUDSAMLSA-N Lys-Asn-Asn Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O ABHIXYDMILIUKV-CIUDSAMLSA-N 0.000 description 1
- DEFGUIIUYAUEDU-ZPFDUUQYSA-N Lys-Asn-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O DEFGUIIUYAUEDU-ZPFDUUQYSA-N 0.000 description 1
- OPTCSTACHGNULU-DCAQKATOSA-N Lys-Cys-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN OPTCSTACHGNULU-DCAQKATOSA-N 0.000 description 1
- VSRXPEHZMHSFKU-IUCAKERBSA-N Lys-Gln-Gly Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O VSRXPEHZMHSFKU-IUCAKERBSA-N 0.000 description 1
- DTUZCYRNEJDKSR-NHCYSSNCSA-N Lys-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN DTUZCYRNEJDKSR-NHCYSSNCSA-N 0.000 description 1
- YDDDRTIPNTWGIG-SRVKXCTJSA-N Lys-Lys-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O YDDDRTIPNTWGIG-SRVKXCTJSA-N 0.000 description 1
- GHKXHCMRAUYLBS-CIUDSAMLSA-N Lys-Ser-Asn Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O GHKXHCMRAUYLBS-CIUDSAMLSA-N 0.000 description 1
- SQXZLVXQXWILKW-KKUMJFAQSA-N Lys-Ser-Phe Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O SQXZLVXQXWILKW-KKUMJFAQSA-N 0.000 description 1
- UIJVKVHLCQSPOJ-XIRDDKMYSA-N Lys-Ser-Trp Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O UIJVKVHLCQSPOJ-XIRDDKMYSA-N 0.000 description 1
- PELXPRPDQRFBGQ-KKUMJFAQSA-N Lys-Tyr-Asn Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCCCN)N)O PELXPRPDQRFBGQ-KKUMJFAQSA-N 0.000 description 1
- VKCPHIOZDWUFSW-ONGXEEELSA-N Lys-Val-Gly Chemical compound OC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN VKCPHIOZDWUFSW-ONGXEEELSA-N 0.000 description 1
- TXTZMVNJIRZABH-ULQDDVLXSA-N Lys-Val-Phe Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 TXTZMVNJIRZABH-ULQDDVLXSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- HLQWFLJOJRFXHO-CIUDSAMLSA-N Met-Glu-Ser Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O HLQWFLJOJRFXHO-CIUDSAMLSA-N 0.000 description 1
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- UHRNIXJAGGLKHP-DLOVCJGASA-N Phe-Ala-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O UHRNIXJAGGLKHP-DLOVCJGASA-N 0.000 description 1
- QCHNRQQVLJYDSI-DLOVCJGASA-N Phe-Asn-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 QCHNRQQVLJYDSI-DLOVCJGASA-N 0.000 description 1
- HCTXJGRYAACKOB-SRVKXCTJSA-N Phe-Asn-Asp Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N HCTXJGRYAACKOB-SRVKXCTJSA-N 0.000 description 1
- UUWCIPUVJJIEEP-SRVKXCTJSA-N Phe-Asn-Cys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CS)C(=O)O)N UUWCIPUVJJIEEP-SRVKXCTJSA-N 0.000 description 1
- NKLDZIPTGKBDBB-HTUGSXCWSA-N Phe-Gln-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC1=CC=CC=C1)N)O NKLDZIPTGKBDBB-HTUGSXCWSA-N 0.000 description 1
- HOYQLNNGMHXZDW-KKUMJFAQSA-N Phe-Glu-Arg Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O HOYQLNNGMHXZDW-KKUMJFAQSA-N 0.000 description 1
- KJJROSNFBRWPHS-JYJNAYRXSA-N Phe-Glu-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O KJJROSNFBRWPHS-JYJNAYRXSA-N 0.000 description 1
- NAXPHWZXEXNDIW-JTQLQIEISA-N Phe-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H](N)CC1=CC=CC=C1 NAXPHWZXEXNDIW-JTQLQIEISA-N 0.000 description 1
- SMFGCTXUBWEPKM-KBPBESRZSA-N Phe-Leu-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 SMFGCTXUBWEPKM-KBPBESRZSA-N 0.000 description 1
- YTILBRIUASDGBL-BZSNNMDCSA-N Phe-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 YTILBRIUASDGBL-BZSNNMDCSA-N 0.000 description 1
- CJAHQEZWDZNSJO-KKUMJFAQSA-N Phe-Lys-Cys Chemical compound NCCCC[C@@H](C(=O)N[C@@H](CS)C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 CJAHQEZWDZNSJO-KKUMJFAQSA-N 0.000 description 1
- ZUQACJLOHYRVPJ-DKIMLUQUSA-N Phe-Lys-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1=CC=CC=C1 ZUQACJLOHYRVPJ-DKIMLUQUSA-N 0.000 description 1
- RVEVENLSADZUMS-IHRRRGAJSA-N Phe-Pro-Asn Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O RVEVENLSADZUMS-IHRRRGAJSA-N 0.000 description 1
- AFNJAQVMTIQTCB-DLOVCJGASA-N Phe-Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=CC=C1 AFNJAQVMTIQTCB-DLOVCJGASA-N 0.000 description 1
- IAOZOFPONWDXNT-IXOXFDKPSA-N Phe-Ser-Thr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O IAOZOFPONWDXNT-IXOXFDKPSA-N 0.000 description 1
- LTAWNJXSRUCFAN-UNQGMJICSA-N Phe-Thr-Arg Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O LTAWNJXSRUCFAN-UNQGMJICSA-N 0.000 description 1
- BQMFWUKNOCJDNV-HJWJTTGWSA-N Phe-Val-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O BQMFWUKNOCJDNV-HJWJTTGWSA-N 0.000 description 1
- VDTYRPWRWRCROL-UFYCRDLUSA-N Phe-Val-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 VDTYRPWRWRCROL-UFYCRDLUSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010035737 Pneumonia viral Diseases 0.000 description 1
- HFZNNDWPHBRNPV-KZVJFYERSA-N Pro-Ala-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O HFZNNDWPHBRNPV-KZVJFYERSA-N 0.000 description 1
- LNLNHXIQPGKRJQ-SRVKXCTJSA-N Pro-Arg-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H]1CCCN1 LNLNHXIQPGKRJQ-SRVKXCTJSA-N 0.000 description 1
- ZSKJPKFTPQCPIH-RCWTZXSCSA-N Pro-Arg-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ZSKJPKFTPQCPIH-RCWTZXSCSA-N 0.000 description 1
- HQVPQXMCQKXARZ-FXQIFTODSA-N Pro-Cys-Ser Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)O HQVPQXMCQKXARZ-FXQIFTODSA-N 0.000 description 1
- ZPPVJIJMIKTERM-YUMQZZPRSA-N Pro-Gln-Gly Chemical compound OC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]1CCCN1 ZPPVJIJMIKTERM-YUMQZZPRSA-N 0.000 description 1
- JMVQDLDPDBXAAX-YUMQZZPRSA-N Pro-Gly-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 JMVQDLDPDBXAAX-YUMQZZPRSA-N 0.000 description 1
- BUEIYHBJHCDAMI-UFYCRDLUSA-N Pro-Phe-Phe Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O BUEIYHBJHCDAMI-UFYCRDLUSA-N 0.000 description 1
- KDBHVPXBQADZKY-GUBZILKMSA-N Pro-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 KDBHVPXBQADZKY-GUBZILKMSA-N 0.000 description 1
- WVXQQUWOKUZIEG-VEVYYDQMSA-N Pro-Thr-Asn Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O WVXQQUWOKUZIEG-VEVYYDQMSA-N 0.000 description 1
- AJJDPGVVNPUZCR-RHYQMDGZSA-N Pro-Thr-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@@H]1CCCN1)O AJJDPGVVNPUZCR-RHYQMDGZSA-N 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- YQHZVYJAGWMHES-ZLUOBGJFSA-N Ser-Ala-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YQHZVYJAGWMHES-ZLUOBGJFSA-N 0.000 description 1
- OOKCGAYXSNJBGQ-ZLUOBGJFSA-N Ser-Asn-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O OOKCGAYXSNJBGQ-ZLUOBGJFSA-N 0.000 description 1
- KAAPNMOKUUPKOE-SRVKXCTJSA-N Ser-Asn-Phe Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 KAAPNMOKUUPKOE-SRVKXCTJSA-N 0.000 description 1
- CXBFHZLODKPIJY-AAEUAGOBSA-N Ser-Gly-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CO)N CXBFHZLODKPIJY-AAEUAGOBSA-N 0.000 description 1
- LRZLZIUXQBIWTB-KATARQTJSA-N Ser-Lys-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LRZLZIUXQBIWTB-KATARQTJSA-N 0.000 description 1
- QYBRQMLZDDJBSW-AVGNSLFASA-N Ser-Tyr-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O QYBRQMLZDDJBSW-AVGNSLFASA-N 0.000 description 1
- TYVAWPFQYFPSBR-BFHQHQDPSA-N Thr-Ala-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)NCC(O)=O TYVAWPFQYFPSBR-BFHQHQDPSA-N 0.000 description 1
- TZKPNGDGUVREEB-FOHZUACHSA-N Thr-Asn-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O TZKPNGDGUVREEB-FOHZUACHSA-N 0.000 description 1
- SKHPKKYKDYULDH-HJGDQZAQSA-N Thr-Asn-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O SKHPKKYKDYULDH-HJGDQZAQSA-N 0.000 description 1
- OJRNZRROAIAHDL-LKXGYXEUSA-N Thr-Asn-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O OJRNZRROAIAHDL-LKXGYXEUSA-N 0.000 description 1
- WLDUCKSCDRIVLJ-NUMRIWBASA-N Thr-Gln-Asp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N)O WLDUCKSCDRIVLJ-NUMRIWBASA-N 0.000 description 1
- RKDFEMGVMMYYNG-WDCWCFNPSA-N Thr-Gln-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O RKDFEMGVMMYYNG-WDCWCFNPSA-N 0.000 description 1
- JMGJDTNUMAZNLX-RWRJDSDZSA-N Thr-Glu-Ile Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JMGJDTNUMAZNLX-RWRJDSDZSA-N 0.000 description 1
- KBBRNEDOYWMIJP-KYNKHSRBSA-N Thr-Gly-Thr Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)O)N)O KBBRNEDOYWMIJP-KYNKHSRBSA-N 0.000 description 1
- GXUWHVZYDAHFSV-FLBSBUHZSA-N Thr-Ile-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GXUWHVZYDAHFSV-FLBSBUHZSA-N 0.000 description 1
- MEJHFIOYJHTWMK-VOAKCMCISA-N Thr-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)[C@@H](C)O MEJHFIOYJHTWMK-VOAKCMCISA-N 0.000 description 1
- TZJSEJOXAIWOST-RHYQMDGZSA-N Thr-Lys-Arg Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CCCN=C(N)N TZJSEJOXAIWOST-RHYQMDGZSA-N 0.000 description 1
- HPQHHRLWSAMMKG-KATARQTJSA-N Thr-Lys-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)O)N)O HPQHHRLWSAMMKG-KATARQTJSA-N 0.000 description 1
- NZRUWPIYECBYRK-HTUGSXCWSA-N Thr-Phe-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O NZRUWPIYECBYRK-HTUGSXCWSA-N 0.000 description 1
- VTMGKRABARCZAX-OSUNSFLBSA-N Thr-Pro-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)[C@@H](C)O VTMGKRABARCZAX-OSUNSFLBSA-N 0.000 description 1
- GVMXJJAJLIEASL-ZJDVBMNYSA-N Thr-Pro-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O GVMXJJAJLIEASL-ZJDVBMNYSA-N 0.000 description 1
- STUAPCLEDMKXKL-LKXGYXEUSA-N Thr-Ser-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O STUAPCLEDMKXKL-LKXGYXEUSA-N 0.000 description 1
- QYDKSNXSBXZPFK-ZJDVBMNYSA-N Thr-Thr-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QYDKSNXSBXZPFK-ZJDVBMNYSA-N 0.000 description 1
- YRJOLUDFVAUXLI-GSSVUCPTSA-N Thr-Thr-Asp Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(O)=O YRJOLUDFVAUXLI-GSSVUCPTSA-N 0.000 description 1
- BBPCSGKKPJUYRB-UVOCVTCTSA-N Thr-Thr-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O BBPCSGKKPJUYRB-UVOCVTCTSA-N 0.000 description 1
- KPMIQCXJDVKWKO-IFFSRLJSSA-N Thr-Val-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O KPMIQCXJDVKWKO-IFFSRLJSSA-N 0.000 description 1
- ICNFHVUVCNWUAB-SZMVWBNQSA-N Trp-Arg-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N ICNFHVUVCNWUAB-SZMVWBNQSA-N 0.000 description 1
- VUMCLPHXCBIJJB-PMVMPFDFSA-N Trp-Phe-His Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)N VUMCLPHXCBIJJB-PMVMPFDFSA-N 0.000 description 1
- BURPTJBFWIOHEY-UWJYBYFXSA-N Tyr-Ala-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 BURPTJBFWIOHEY-UWJYBYFXSA-N 0.000 description 1
- QYSBJAUCUKHSLU-JYJNAYRXSA-N Tyr-Arg-Val Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(O)=O QYSBJAUCUKHSLU-JYJNAYRXSA-N 0.000 description 1
- QHEGAOPHISYNDF-XDTLVQLUSA-N Tyr-Gln-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC1=CC=C(C=C1)O)N QHEGAOPHISYNDF-XDTLVQLUSA-N 0.000 description 1
- CKHQKYHIZCRTAP-SOUVJXGZSA-N Tyr-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)O CKHQKYHIZCRTAP-SOUVJXGZSA-N 0.000 description 1
- MPKPIWFFDWVJGC-IRIUXVKKSA-N Tyr-Gln-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC1=CC=C(C=C1)O)N)O MPKPIWFFDWVJGC-IRIUXVKKSA-N 0.000 description 1
- CTDPLKMBVALCGN-JSGCOSHPSA-N Tyr-Gly-Val Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O CTDPLKMBVALCGN-JSGCOSHPSA-N 0.000 description 1
- NKUGCYDFQKFVOJ-JYJNAYRXSA-N Tyr-Leu-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 NKUGCYDFQKFVOJ-JYJNAYRXSA-N 0.000 description 1
- OLYXUGBVBGSZDN-ACRUOGEOSA-N Tyr-Leu-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 OLYXUGBVBGSZDN-ACRUOGEOSA-N 0.000 description 1
- WURLIFOWSMBUAR-SLFFLAALSA-N Tyr-Phe-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC3=CC=C(C=C3)O)N)C(=O)O WURLIFOWSMBUAR-SLFFLAALSA-N 0.000 description 1
- XJPXTYLVMUZGNW-IHRRRGAJSA-N Tyr-Pro-Asp Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O XJPXTYLVMUZGNW-IHRRRGAJSA-N 0.000 description 1
- NHOVZGFNTGMYMI-KKUMJFAQSA-N Tyr-Ser-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 NHOVZGFNTGMYMI-KKUMJFAQSA-N 0.000 description 1
- UMSZZGTXGKHTFJ-SRVKXCTJSA-N Tyr-Ser-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 UMSZZGTXGKHTFJ-SRVKXCTJSA-N 0.000 description 1
- LUMQYLVYUIRHHU-YJRXYDGGSA-N Tyr-Ser-Thr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LUMQYLVYUIRHHU-YJRXYDGGSA-N 0.000 description 1
- BIVIUZRBCAUNPW-JRQIVUDYSA-N Tyr-Thr-Asn Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O BIVIUZRBCAUNPW-JRQIVUDYSA-N 0.000 description 1
- AFWXOGHZEKARFH-ACRUOGEOSA-N Tyr-Tyr-His Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CC=C(O)C=C1 AFWXOGHZEKARFH-ACRUOGEOSA-N 0.000 description 1
- NWEGIYMHTZXVBP-JSGCOSHPSA-N Tyr-Val-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O NWEGIYMHTZXVBP-JSGCOSHPSA-N 0.000 description 1
- RVGVIWNHABGIFH-IHRRRGAJSA-N Tyr-Val-Ser Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O RVGVIWNHABGIFH-IHRRRGAJSA-N 0.000 description 1
- BYOHPUZJVXWHAE-BYULHYEWSA-N Val-Asn-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)N BYOHPUZJVXWHAE-BYULHYEWSA-N 0.000 description 1
- LNYOXPDEIZJDEI-NHCYSSNCSA-N Val-Asn-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)N LNYOXPDEIZJDEI-NHCYSSNCSA-N 0.000 description 1
- KXUKIBHIVRYOIP-ZKWXMUAHSA-N Val-Asp-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N KXUKIBHIVRYOIP-ZKWXMUAHSA-N 0.000 description 1
- TZVUSFMQWPWHON-NHCYSSNCSA-N Val-Asp-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C(C)C)N TZVUSFMQWPWHON-NHCYSSNCSA-N 0.000 description 1
- FPCIBLUVDNXPJO-XPUUQOCRSA-N Val-Cys-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CS)C(=O)NCC(O)=O FPCIBLUVDNXPJO-XPUUQOCRSA-N 0.000 description 1
- AGKDVLSDNSTLFA-UMNHJUIQSA-N Val-Gln-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N1CCC[C@@H]1C(=O)O)N AGKDVLSDNSTLFA-UMNHJUIQSA-N 0.000 description 1
- VVZDBPBZHLQPPB-XVKPBYJWSA-N Val-Glu-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O VVZDBPBZHLQPPB-XVKPBYJWSA-N 0.000 description 1
- ZHQWPWQNVRCXAX-XQQFMLRXSA-N Val-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C(C)C)N ZHQWPWQNVRCXAX-XQQFMLRXSA-N 0.000 description 1
- BTWMICVCQLKKNR-DCAQKATOSA-N Val-Leu-Ser Chemical compound CC(C)[C@H]([NH3+])C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C([O-])=O BTWMICVCQLKKNR-DCAQKATOSA-N 0.000 description 1
- XXWBHOWRARMUOC-NHCYSSNCSA-N Val-Lys-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)O)N XXWBHOWRARMUOC-NHCYSSNCSA-N 0.000 description 1
- UGFMVXRXULGLNO-XPUUQOCRSA-N Val-Ser-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O UGFMVXRXULGLNO-XPUUQOCRSA-N 0.000 description 1
- NZYNRRGJJVSSTJ-GUBZILKMSA-N Val-Ser-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O NZYNRRGJJVSSTJ-GUBZILKMSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 108010024078 alanyl-glycyl-serine Proteins 0.000 description 1
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 1
- 108010041407 alanylaspartic acid Proteins 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 108010013835 arginine glutamate Proteins 0.000 description 1
- 108010008355 arginyl-glutamine Proteins 0.000 description 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 1
- 108010047857 aspartylglycine Proteins 0.000 description 1
- 108010092854 aspartyllysine Proteins 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 239000011258 core-shell material Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 108010054812 diprotin A Proteins 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000007499 fusion processing Methods 0.000 description 1
- 108010015792 glycyllysine Proteins 0.000 description 1
- 108010081551 glycylphenylalanine Proteins 0.000 description 1
- 108010037850 glycylvaline Proteins 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010212 intracellular staining Methods 0.000 description 1
- 108010027338 isoleucylcysteine Proteins 0.000 description 1
- 108010053037 kyotorphin Proteins 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 108010090333 leucyl-lysyl-proline Proteins 0.000 description 1
- 108010047926 leucyl-lysyl-tyrosine Proteins 0.000 description 1
- 108010073472 leucyl-prolyl-proline Proteins 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 108010070409 phenylalanyl-glycyl-glycine Proteins 0.000 description 1
- 108010018625 phenylalanylarginine Proteins 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 108010079317 prolyl-tyrosine Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 108010003137 tyrosyltyrosine Proteins 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 108010009962 valyltyrosine Proteins 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 208000009421 viral pneumonia Diseases 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种新型冠状病毒亚单位纳米疫苗制备方法和应用,所述纳米疫苗包含SARS‑CoV‑2病毒棘突蛋白的S1亚基蛋白、单磷脂酰A、CpG寡脱氧核苷酸、阳离子脂质和辅助脂质,制备得到的纳米颗粒尺寸均匀。动物实验结果显示,纳米疫苗组比游离抗原/单磷脂酰A、CpG寡脱氧核苷酸组、游离抗原/铝佐剂组具有更强的激活体液免疫、细胞免疫的能力。本发明对于预防或治疗由SARS‑CoV‑2引起的COVID‑19具有重要的应用价值。
Description
技术领域
本发明涉及生物医药技术领域。更具体地,涉及一种新型冠状病毒亚单位纳米疫苗的制备和应用。
背景技术
SARS-CoV-2是新型冠状病毒,在系统分类上属于冠状病毒科(Coronaviridae) 冠状病毒属(Coronavirus)。为正链RNA病毒,由棘突蛋白(spike protein)、包膜蛋白(envelope protein)、膜蛋白(membrane protein)和核蛋白(nucleoprotein) 组成病毒结构。棘突蛋白(spike protein)含有两个亚基:S1和S2,S1主要包含受体结合区域(RBD),识别细胞膜表面的血管紧张素转换酶(ACE)2——ACE2 受体,S2在病毒膜融合过程中起作用。
根据基因组与结构的不同,冠状病毒被分为4大类,α、β、γ、δ,其中α类与β类只感染哺乳动物,γ类与δ类则主要感染鸟类。感染人的冠状病毒主要有七种(包括新发现的SARS-COV-2),α属的HCoV-229E、HCoV-OC43、HCoV-NL63 和HCoV-HKU1,感染人上呼吸道,导致感冒和类似感冒的症状,不会导致死亡。而β属的SARS和MERS病毒会感染人的下呼吸道,导致病毒性肺炎综合症,有较高死亡率。研究发现,SARS-COV-2有79.5%的病毒基因序列与SARS-CoV 相同,40%的病毒基因组序列与MERS-CoV相同。目前临床上尚无有效药物治疗SARS-COV-2引起的肺炎,接种疫苗是阻断病毒传播,保护人群免受感染的有效措施。相对于灭活病毒疫苗需要产生大量的感染性病毒,要在P3实验室高度谨慎进行的安全问题,病毒的亚单位蛋白疫苗更加安全,并且生产成本更低。
SARS-CoV-2的S蛋白通过与宿主细胞膜上的ACE2受体相结合,在病毒感染宿主中起重要作用。S蛋白由两个亚基组成,S1、S2亚基,S1亚基主要与宿主细胞膜受体ACE2相结合,S2在促进膜融合中起主要作用。因此,以S1亚基作为主要靶点进行亚单位疫苗的制备,对于预防或治疗由SARS-CoV-2引起的 COVID-19具有重要的应用价值。目前还未见有针对SARS-COV-2的S1蛋白作为抗原,制备亚单位蛋白疫苗的相关报道,由于亚单位蛋白存在免疫原型弱的问题,如何提高其免疫原性也是一个亟待解决的问题。
发明内容
本发明的目的在于克服现有技术中存在的上述缺陷和不足,提供一种纳米颗粒。
本发明的另一目在于提供上述纳米颗粒的制备方法。
本发明的第三个目的在于提供上述纳米颗粒的应用。
为了实现上述目的,本发明是通过以下方案实现的:
一种纳米颗粒,包含SARS-CoV-2棘突蛋白的S1亚基蛋白、免疫佐剂、阳离子脂质和辅助脂质。
本发明通过阳离子脂质与S1蛋白亚基静电相互作用,以辅助脂质为稳定剂,对免疫佐剂进行包裹,形成本发明的纳米颗粒能够产生较强的体液免疫,使细胞免疫明显增强。
优选地,所述纳米颗粒为脂质体核壳结构,核内为免疫佐剂,壳为包裹在核上的阳离子脂质和辅助脂质,脂质体壳表面负载S1亚基蛋白;或核内为部分免疫佐剂,壳为包裹在核上的阳离子脂质和辅助脂质,颗粒表面负载S1亚基蛋白和另外部分免疫佐剂。
优选地,所述S1亚基蛋白为重组蛋白,由293T真核表达系统表达产生,具有如SEQID NO:1所示的氨基酸序列。
优选地,所述免疫佐剂为单磷脂酰A和/或CpG寡脱氧核苷酸。
优选地,所述CpG为CpGODN。
优选地,所述CpGODN具有如SEQ ID NO:2所示的核酸序列。
优选地,所述阳离子脂质为溴化三甲基-2,3-二油酰氧基丙基铵(DOTAP)。
优选地,辅助脂质为二油酰基磷脂酰乙醇胺(DOPE)和/或胆固醇(Chol)。
优选地,所述纳米颗粒为近似球形。
优选地,所述纳米颗粒的粒径为30~200nm,例如30~60nm、60~90nm、90~120nm、120~150nm或150~200nm。
优选地,所述纳米颗粒的Zeta电位+10至+60mV,例如+10至+15mV,+15 至+20mV、+20至+25mV、+25至+30mV、+30至+40mV、+40至+50mV、+50 至60mV。
优选地,所述溴化三甲基-2,3-二油酰氧基丙基铵(DOTAP)、二油酰基磷脂酰乙醇胺(DOPE)和胆固醇(Chol)的质量比为1.5:0.5:0.2。
优选地,所述S1亚基蛋白(SP)、单磷脂酰A(MPLA)、CpG寡脱氧核苷酸(CpG)、溴化三甲基-2,3-二油酰氧基丙基铵(DOTAP)、二油酰基磷脂酰乙醇胺(DOPE)和胆固醇(Chol)的质量比为5~20:0.5~1.5:1~2:150: 50:20。
上述纳米颗粒的制备方法,包括如下步骤:
S1.提供包含阳离子脂质的溶液、包含辅助脂质的溶液、包含佐剂MPLA的溶液、包含佐剂CpG ODN的溶液和包含SARS-CoV-2S1亚基蛋白的溶液;
S2.将包含阳离子脂质的溶液、包含辅助脂质的溶液、包含佐剂MPLA的溶液混合均匀,除溶剂,获得脂质膜;
S3a.向步骤S2制备得到的脂质膜加入去离子水震荡,超声,过膜得到脂质体;
S4a.将步骤S3a制备得到的脂质体与步骤S1中包含SARS-CoV-2S1亚基蛋白的溶液和包含佐剂CpG ODN的溶液混匀,得到Lipo(M)-CpG-SP颗粒溶液;
或
S3b.向步骤S2制备得到的脂质膜加入包含佐剂CpG ODN的溶液,超声,过膜得到脂质体;
S4b.将步骤S3b制备得到的脂质体与包含SARS-CoV-2S1亚基蛋白的溶液混匀,得到Lipo(M+CpG)-SP颗粒溶液;
优选地,所述阳离子脂质为溴化三甲基-2,3-二油酰氧基丙基铵(DOTAP),辅助脂质为二油酰基磷脂酰乙醇胺(DOPE)和胆固醇(Chol)。
作为一种优选地可实施方式,上述纳米颗粒的制备方法,包括如下步骤:
S1.将溴化三甲基-2,3-二油酰氧基丙基铵(DOTAP)、二油酰基磷脂酰乙醇胺(DOPE)、胆固醇(Chol)、单磷脂酰A(MPLA)分别溶解于乙醇中,配置浓度分别为700μg/mL,200μg/mL,100μg/mL,10μg/mL;CpG寡脱氧核苷酸溶解在水中,配置浓度为24.9μg/mL;S1亚基蛋白溶解于水中,配置浓度为 0.5~1mg/mL;
S2.将步骤S1配置的溴化三甲基-2,3-二油酰氧基丙基铵(DOTAP)、二油酰基磷脂酰乙醇胺(DOPE)、胆固醇(Chol)、单磷脂酰A乙醇溶液按照150: 50:20:1的质量比混合均匀,45℃真空旋转蒸发去除有机溶剂获得脂质膜;
S3.向步骤S2制备得到的脂质膜加入去离子水震荡,超声10分钟,过膜得到脂质体;
S4.将步骤S3制备得到的脂质体、步骤S1中配置的S1亚基蛋白水溶液和 CpG寡脱氧核苷酸水溶液混合,得到Lipo(M)-CpG-SP溶液,再进行冻干浓缩即得到Lipo(M)-CpG-SP脂质体颗粒。最终,所述纳米颗粒中S1亚基蛋白(SP)、单磷脂酰A(MPLA)、CpG寡脱氧核苷酸(CpG)、溴化三甲基-2,3-二油酰氧基丙基铵(DOTAP)、二油酰基磷脂酰乙醇胺(DOPE)和胆固醇(Chol)的质量比为10:1:1.5:150:50:20。
作为另一种优选地方式,上述纳米颗粒的制备包括如下步骤:
S1.将溴化三甲基-2,3-二油酰氧基丙基铵(DOTAP)、二油酰基磷脂酰乙醇胺(DOPE)、胆固醇(Chol)、单磷脂酰A(MPLA)分别溶解于乙醇中,配置浓度分别为700μg/mL,200μg/mL,100μg/mL,10μg/mL;CpG寡脱氧核苷酸溶解在水中,配置浓度为24.9μg/mL;S1亚基蛋白溶解于水中,配置浓度为 0.5~1mg/mL;
S2.将步骤S1配置的溴化三甲基-2,3-二油酰氧基丙基铵(DOTAP)、二油酰基磷脂酰乙醇胺(DOPE)、胆固醇(Chol)、单磷脂酰A乙醇溶液按照150: 50:20:1的质量比混合均匀,45℃真空旋转蒸发去除有机溶剂获得脂质膜;
S3.向步骤S2制备得到的脂质膜加入步骤S1制备的CpG寡脱氧核苷酸水溶液震荡,超声10分钟,过膜得到脂质体;
S4.将步骤S3制备得到的脂质体、步骤S1中配置的S1亚基蛋白水溶液混合均匀,得到Lipo(M+CpG)-SP溶液,再进行冻干浓缩即得到Lipo(M+CpG)-SP 脂质体颗粒。最终,所述纳米颗粒中S1亚基蛋白(SP)、单磷脂酰A(MPLA)、 CpG寡脱氧核苷酸(CpG)、溴化三甲基-2,3-二油酰氧基丙基铵(DOTAP)、二油酰基磷脂酰乙醇胺(DOPE)和胆固醇(Chol)的质量比为10:1:1.5:150: 50:20。
本发明选用SARS-COV-2的S1亚基作为抗原,避免直接接触SARS-COV-2 带来的安全风险,在普通实验室中即可开展实验。针对Spike亚单位蛋白免疫原性弱的问题,将其颗粒疫苗的尺寸控制在纳米尺寸,同时共负载TLR激动剂为佐剂,加强功效。
纳米尺寸颗粒具有常规疫苗无法比拟的优势:(1)由于纳米颗粒的尺寸和病原体病毒的尺寸相似,因而能够模拟病原体天然的感染过程从而容易被抗原呈递细胞吸收;(2)纳米颗粒可以共输送抗原和免疫刺激分子,实现抗原和佐剂的共输送;(3)纳米尺寸颗粒可实现靶向淋巴结,并缓释抗原和佐剂,激活T 细胞和B细胞,增强免疫效果。
本发明包裹SARS-CoV-2S1重组蛋白、双免疫佐剂CpG和MPLA的脂质体纳米颗粒疫苗免疫效果明显优于铝佐剂与游离SARS-CoV-2S1重组蛋白的混合物。本发明的纳米疫苗既能够很好的激发Th1型免疫,又能够激活Th2型免疫;能够增加CD4+和CD8+淋巴T细胞IFN-γ,TNF-α和IL-2的表达量,从而增强 T细胞介导的细胞免疫效果。
本发明还请求保护上述纳米颗粒在制备与SARS-CoV-2感染相关疾病的免疫原性组合物中的应用。
优选地,所述免疫原性组合物还包含药学上可接受的辅料,如赋形剂、防腐剂、抗菌剂、额外的免疫佐剂等。
优选地,所述免疫原性组合物为疫苗。
与现有技术相比,本发明的有益效果在于:
(1)本发明以SARS-CoV-2棘突蛋白S1重组蛋白病毒亚单位蛋白为疫苗抗原来制备纳米疫苗,制备得到的纳米颗粒粒径均一,分散性好。
(2)本发明的纳米颗粒施用于动物后,能产生较强的体液免疫,使细胞免疫明显增强,免疫效果优于游离形式的抗原/佐剂混合注射组以及游离抗原/铝佐剂组的疫苗。
(3)本发明的纳米颗粒能够通过简单的方法制备,品质稳定,易于产业化生产。
附图说明
图1为本发明实施例1制备的五种纳米颗粒的粒径分布。
图2为本发明实施例1制备的五种纳米颗粒的表面电位。通过筛选不同比例的DOTAP、DOPE、CHOL和MPLA去制备Lipo(M)纳米颗粒,最终我们确定制备Lipo(M)纳米颗粒的最优比例为DOTAP、DOPE、CHOL和MPLA的最终浓度比为150:50:20:1。
图3为制备过程中产生的五种纳米颗粒的粒径分布;其中1)Lipo(M):MPLA 在脂质层内;2)Lipo(M)-CpG:MPLA在脂质层内,CpG在脂质颗粒表面;3) Lipo(M)-CpG-SP:MPLA在脂质层内,CpG和SP在脂质颗粒表面;4) Lipo(M+CpG):MPLA在脂质层,CpG在亲水核内;5)Lipo(M+CpG)–SP:MPLA 在脂质层,CpG在亲水核内,SP在脂质颗粒表面的粒径分布;如图所示,五种纳米颗粒尺寸均匀,具有较窄的粒径分布。
图4为制备过程中产生的五种纳米颗粒的表面电位;1)Lipo(M);2) Lipo(M)-CpG;3)Lipo(M)-CpG-SP;4)Lipo(M+CpG);5)Lipo(M+CpG)–SP。
图5为纳米疫苗及各种制剂免疫动物的方案。
图6为Lipo(M)-CpG-SP,Lipo(M+CpG)-SP对小鼠进行第一次免疫后的第 14天,小鼠血清中IgG的滴度,以游离的佐剂MPLA,CpG,S1蛋白和游离的 S1蛋白和铝佐剂做为对照组,*P<0.05,**P<0.01和***P<0.001。
图7为Lipo(M)-CpG-SP,Lipo(M+CpG)-SP对小鼠进行第一次免疫后的第 14天,IgG1的滴度,以游离的佐剂MPLA,CpG,S1蛋白和游离的S1蛋白和铝佐剂做为对照组,*P<0.05,**P<0.01和***P<0.001。
图8为Lipo(M)-CpG-SP,Lipo(M+CpG)-SP对小鼠进行第一次免疫后的第 14天,IgG2a的滴度,以游离的佐剂MPLA,CpG,S1蛋白和游离的S1蛋白和铝佐剂做为对照组,*P<0.05,**P<0.01和***P<0.001。
图9为Lipo(M)-CpG-SP,Lipo(M+CpG)-SP对小鼠进行第一次免疫后的第 14天,IgG2a/IgG1的比例,以游离的佐剂MPLA,CpG,S1蛋白和游离的S1 蛋白和铝佐剂做为对照组,*P<0.05,**P<0.01和***P<0.001。实验结果表明,使用本发明的纳米颗粒对小鼠进行免疫后,能够促进T细胞的极化,增强细胞免疫的效果。
图10为Lipo(M)-CpG-SP,Lipo(M+CpG)-SP对小鼠进行第一次免疫后的第 28天,IgG的滴度,以游离的佐剂MPLA,CpG,S1蛋白和游离的S1蛋白和铝佐剂做为对照组,*P<0.05,**P<0.01和***P<0.001。
图11为Lipo(M)-CpG-SP,Lipo(M+CpG)-SP对小鼠进行第一次免疫后的第 28天,IgG1的滴度,以游离的佐剂MPLA,CpG,S1蛋白和游离的S1蛋白和铝佐剂做为对照组,*P<0.05,**P<0.01和***P<0.001。
图12为Lipo(M)-CpG-SP,Lipo(M+CpG)-SP对小鼠进行第一次免疫后的第 28天,IgG2a的滴度,以游离的佐剂MPLA,CpG,S1蛋白和游离的S1蛋白和铝佐剂做为对照组,*P<0.05,**P<0.01和***P<0.001。
图13为Lipo(M)-CpG-SP,Lipo(M+CpG)-SP对小鼠进行第一次免疫后的第28天,IgG2a/IgG1的比例,以游离的佐剂MPLA,CpG,S1蛋白和游离的S1 蛋白和铝佐剂做为对照组,*P<0.05,**P<0.01和***P<0.001。
图14为Lipo(M)-CpG-SP,Lipo(M+CpG)-SP对小鼠进行第一次免疫后的第 42天,IgG的滴度,以游离的佐剂MPLA,CpG,S1蛋白和游离的S1蛋白和铝佐剂做为对照组,*P<0.05,**P<0.01和***P<0.001。
图15为Lipo(M)-CpG-SP,Lipo(M+CpG)-SP对小鼠进行第一次免疫后的第 42天,IgG1的滴度,以游离的佐剂MPLA,CpG,S1蛋白和游离的S1蛋白和铝佐剂做为对照组,*P<0.05,**P<0.01和***P<0.001。
图16为Lipo(M)-CpG-SP,Lipo(M+CpG)-SP对小鼠进行第一次免疫后的第 42天,IgG2a的滴度,以游离的佐剂MPLA,CpG,S1蛋白和游离的S1蛋白和铝佐剂做为对照组,*P<0.05,**P<0.01和***P<0.001。
图17为Lipo(M)-CpG-SP,Lipo(M+CpG)-SP对小鼠进行第一次免疫后的第 42天,IgG2a/IgG1的比例,以游离的佐剂MPLA,CpG,S1蛋白和游离的S1 蛋白和铝佐剂做为对照组,*P<0.05,**P<0.01和***P<0.001。
图18为用抗原刺激各组小鼠免疫后的CD4+淋巴T细胞内IFN-γ,TNF-α和 IL-2的表达量。
图19为用抗原刺激各组小鼠免疫后的CD8+淋巴T细胞内IFN-γ,TNF-α和 IL-2的表达量。
具体实施方式
以下结合说明书附图和具体实施例来进一步说明本发明,但实施例并不对本发明做任何形式的限定。除非特别说明,本发明采用的试剂、方法和设备为本技术领域常规试剂、方法和设备。
实施例1 Lipo(M)纳米颗粒的制备
S1.将阳离子聚合物溴化三甲基-2,3-二油酰氧基丙基铵(DOTAP)、辅助脂质二油酰基磷脂酰乙醇胺(DOPE)和胆固醇(Chol)、免疫佐剂单磷脂酰A(MPLA) 分别溶解于乙醇中,在磁力搅拌下溶解得到DOTAP/DOPE浓度为5mg/mL,Chol 浓度为2mg/mL,MPLA浓度为0.01mg/mL;
S2.将步骤S1配置的溴化三甲基-2,3-二油酰氧基丙基铵(DOTAP)、二油酰基磷脂酰乙醇胺(DOPE)、胆固醇(Chol)、单磷脂酰A乙醇溶液配置成含表1中各组分质量比的混合溶液,45℃真空旋转蒸发去除有机溶剂获得脂质膜;
S3.向步骤S2制备得到的脂质膜加入去离子水震荡,超声10分钟,过膜得到脂质体颗粒,进行颗粒尺寸与zeta电位表征,4℃储存过夜,测稳定性;
S4.将步骤S3制备得到的脂质体进行冻干浓缩即得到Lipo(M)纳米颗粒。
表1
序号 | DOTAP:DOPE:CHOL:MPLA |
1 | 1:0.5:0.2:0.01 |
2 | 0.5:1:0.2:0.01 |
3 | 0.5:1.5:0.2:0.01 |
4 | 1:1:0.2:0.01 |
5 | 1.5:0.5:0.2:0.01 |
利用马尔文粒径仪(带有动态光散射检测器)对以上五种纳米颗粒的平均粒径和Zeta电位进行测试,结果如图1和2所示。通过筛选不同比例的DOTAP、 DOPE、CHOL和MPLA去制备Lipo(M)纳米颗粒,最终我们确定制备Lipo(M) 纳米颗粒的最优比例为DOTAP、DOPE、CHOL和MPLA的最终浓度比为150: 50:20:1。制备得到的纳米颗粒粒径均一,分散性好。后续实验制备纳米颗粒时DOTAP、DOPE、CHOL和MPLA这四组分比例选用此最优比例。
实施例2 Lipo(M)-CpG-SP纳米颗粒的制备
1、SARS-CoV-2S1重组蛋白由293T真核表达系统表达产生,其氨基酸序列如SEQ IDNO:1所示;CpG寡脱氧核苷酸(CpG ODN)序列如SEQ ID NO:2 所示。
2、制备过程
S1.将溴化三甲基-2,3-二油酰氧基丙基铵(DOTAP)、二油酰基磷脂酰乙醇胺(DOPE)、胆固醇(Chol)、单磷脂酰A(MPLA)分别溶解于乙醇中,配置浓度分别为700μg/mL,200μg/mL,100μg/mL,10μg/mL;CpG寡脱氧核苷酸溶解在水中,配置浓度为24.9μg/mL;S1亚基蛋白溶解于水中,配置浓度为 0.5~1mg/mL;
S2.按实施例1得到最优Lipo(M)纳米颗粒的比例,将步骤S1配置的溴化三甲基-2,3-二油酰氧基丙基铵(DOTAP)、二油酰基磷脂酰乙醇胺(DOPE)、胆固醇(Chol)、单磷脂酰A乙醇溶液按照150:50:20:1的质量比混合均匀, 45℃真空旋转蒸发去除有机溶剂获得质量比为DOTAP1.5:DOPE0.5:CHOL0.2的脂质膜;
S3.向步骤S2制备得到的脂质膜加入去离子水震荡,超声10分钟,过膜得到脂质体,再与CpG寡脱氧核苷酸水溶液混匀,得到Lipo(M)-CpG脂质颗粒,最终脂质颗粒MPLA和CpG的质量比为1:1.5;
S4.将步骤S3制备得到的脂质颗粒、步骤S1中配置的S1亚基蛋白水溶液混合,得到Lipo(M)-CpG-SP溶液,再进行冻干浓缩即得到Lipo(M)-CpG-SP纳米颗粒。最终,该纳米颗粒中S1亚基蛋白(SP)、单磷脂酰A(MPLA)、CpG 寡脱氧核苷酸(CpG)、溴化三甲基-2,3-二油酰氧基丙基铵(DOTAP)、二油酰基磷脂酰乙醇胺(DOPE)和胆固醇(Chol)的质量比为10:1:1.5:150:50: 20。
实施例3 Lipo(M+CpG)-SP纳米颗粒的制备
1、SARS-CoV-2S1重组蛋白由293T真核表达系统表达产生,其氨基酸序列如SEQ IDNO:1所示。
2、制备过程
S1.将溴化三甲基-2,3-二油酰氧基丙基铵(DOTAP)、二油酰基磷脂酰乙醇胺(DOPE)、胆固醇(Chol)、单磷脂酰A(MPLA)分别溶解于乙醇中,配置浓度分别为700μg/mL,200μg/mL,100μg/mL,10μg/mL;CpG寡脱氧核苷酸溶解在水中,配置浓度为24.9μg/mL;S1亚基蛋白溶解于水中,配置浓度为 0.5~1mg/mL;
S2.将步骤S1配置的溴化三甲基-2,3-二油酰氧基丙基铵(DOTAP)、二油酰基磷脂酰乙醇胺(DOPE)、胆固醇(Chol)、单磷脂酰A乙醇溶液按照150: 50:20:1的质量比混合均匀,45℃真空旋转蒸发去除有机溶剂获得脂质膜;
S3.向步骤S2制备得到的脂质膜加入步骤S1制备的CpG寡脱氧核苷酸水溶液震荡,超声10分钟,过膜得到脂质体,即Lipo(M+CpG)脂质颗粒,最终脂质颗粒MPLA和CpG的质量比为1:1.5;
S4.将步骤S3制备得到的脂质体与步骤S1中配置的S1亚基蛋白水溶液混合,得到Lipo(M+CpG)-SP溶液,再进行冻干浓缩即得到Lipo(M+CpG)-SP纳米颗粒。最终,该纳米颗粒中S1亚基蛋白(SP)、单磷脂酰A(MPLA)、CpG 寡脱氧核苷酸(CpG)、溴化三甲基-2,3-二油酰氧基丙基铵(DOTAP)、二油酰基磷脂酰乙醇胺(DOPE)和胆固醇(Chol)的质量比为10:1:1.5:150:50:20。
实施例4.纳米颗粒粒径测试和电位测试
利用马尔文粒径仪(带有动态光散射检测器)对以上五种纳米颗粒:Lipo(M) (选自实施例1中第5个纳米颗粒)、Lipo(M)-CpG(实施例2制得)、 Lipo(M)-CpG-SP(实施例2制得)、Lipo(M+CpG)(实施例3制得)和 Lipo(M+CpG)–SP(实施例3制得)的平均粒径和Zeta电位进行测试,结果如图 3和4所示。结果显示五种纳米颗粒分布均匀。
实施例5.纳米颗粒在小鼠体内的免疫效果评价
一、免疫方式
将5~8周雌性Balb/c小鼠分为五组,每组10只。采用尾根部皮下注射方式,按照表2中的免疫方案对小鼠进行免疫,并两周加强免疫一次,再间隔一周再次加强免疫一次,共免疫3次。
表2各组免疫类别
二、免疫效果评价
1、小鼠血清中IgG及亚型检测
图3为纳米疫苗免疫动物的方案,分别在第一次免疫后的第14、28天进行眼眶采血,分离血清,Elisa检测血清中IgG,IgG1的滴度。
(1)检测过程
1)将5μg/mL的SARS-CoV-2S1重组蛋白抗原包被在96孔板中,每孔100 μL,4℃过夜包被。
2)过夜包被的板,用PBST洗3次,每次200μL,用200μL 3%BSA在 37℃封闭2h。
3)取2μL免疫血清或阴性对照血清,稀释至200μL,再依次倍比稀释,加入到包被抗原的孔中,室温下孵育2h。
4)清洗5次,加工作浓度的IgG-HRP,每孔100μL,室温孵育2h。
5)清洗5次,每孔加100μL TMB底物,黑暗下孵育20min,用50μL 2M H2SO4终止反应,450nm处检测OD值。
6)计算滴度,若标本孔的平均吸收值(P)与阴性对照平均吸收值(N)的比值(即P/N)大于2.1,则判定标本孔为阳性。
(2)检测结果
图6、7、8、9显示了第一次免疫后的第14天,各组小鼠的血清中IgG,IgG1, IgG2a的滴度及IgG2a/IgG1的比值。结果显示:施予Lipo(M+CpG)-SP小鼠的血清IgG,IgG1,IgG2a滴度高于Free(M+CpG+SP)(施予游离SARS-CoV-2S1重组蛋白,游离MPLA,CpG)和Al+SP组(施予游离SARS-CoV-2S1重组蛋白+ 佐剂),具有极显著性差异(P<0.001);施予Lipo(M)-CpG-SP纳米颗粒溶液小鼠的血清IgG,IgG1,IgG2a滴度高于Free(M+CpG+SP)(施予游离SARS-CoV-2S1重组蛋白,游离MPLA,CpG)和Al+SP组(施予游离SARS-CoV-2S1重组蛋白+佐剂),具有显著性差异(P<0.01);施予Lipo(M+CpG)-SP纳米颗粒溶液的小鼠和施予Lipo(M)-CpG-SP纳米颗粒溶液的小鼠的血清中IgG2a/IgG1高于 Al+SP组(施予游离SARS-CoV-2S1重组蛋白+佐剂),具有显著性差异(P<0.05)。
图10、11、12、13显示了一次免疫后的第28天,即第二次免疫后14天各组小鼠的血清中IgG,IgG1,IgG2a的滴度及IgG2a/IgG1的比值。结果显示:施予Lipo(M+CpG)-SP,Lipo(M)-CpG-SP组小鼠的血清IgG,IgG1,IgG2a滴度显著高于Al+SP组(施予游离SARS-CoV-2S1重组蛋白+佐剂,P<0.001);施予 Lipo(M+CpG)-SP,Lipo(M)-CpG-SP组以及Free(M+CpG+SP)(施予游离 SARS-CoV-2S1重组蛋白,游离MPLA,CpG)的小鼠的血清中IgG2a/IgG1高于Al+SP组(施予游离SARS-CoV-2S1重组蛋白+佐剂),具有显著性差异(P< 0.05)。
图14、15、16、17显示了一次免疫后的第42天,即第三次免疫后14天各组小鼠的血清中IgG,IgG1,IgG2a的滴度及IgG2a/IgG1的比值。结果显示:施予Lipo(M+CpG)-SP,Lipo(M)-CpG-SP组小鼠的血清IgG,IgG1,IgG2a滴度高于Free(M+CpG+SP)(施予游离SARS-CoV-2S1重组蛋白,游离MPLA,CpG),具有显著性差异(P<0.05),且高于Al+SP组(施予游离SARS-CoV-2S1重组蛋白+佐剂),具有极显著性差异(P<0.001);施予Lipo(M+CpG)-SP, Lipo(M)-CpG-SP组以及Free(M+CpG+SP)(施予游离SARS-CoV-2S1重组蛋白, 游离MPLA,CpG)的小鼠的血清中IgG2a/IgG1高于Al+SP组(施予游离 SARS-CoV-2S1重组蛋白+佐剂),P值分别为(P<0.001,<0.05,P<0.01)。
以上实验结果表明,本发明的包裹SARS-CoV-2S1重组蛋白、双免疫佐剂 CpG和MPLA的脂质体纳米颗粒对小鼠进行免疫后,能够促进T细胞的极化,能够增强体液免疫,提高抗体的滴度。本发明的纳米颗粒的免疫效果明显优于铝佐剂与游离SARS-CoV-2S1重组蛋白的混合物,能够增强体液免疫,提高抗体的滴度。本发明的包裹SARS-CoV-2S1重组蛋白、双免疫佐剂CpG和MPLA的两种脂质体纳米颗粒既能够很好的激发Th1型免疫,又能够激活Th2型免疫。
2、小鼠外周血C84+,CD8+T细胞胞内因子检测
(1)检测过程
第一次免疫后的第32天,取各组小鼠外周血,300μL/只,通过红细胞裂解液去除红细胞;通过表面抗体标记CD3,CD4,CD8,然后胞内染色IFN-γ,TNF-α, IL-2;最后流式细胞仪检测并分析。
(2)检测结果
图18为用抗原刺激各组小鼠免疫后的CD4+淋巴T细胞内IFN-γ,TNF-α和IL-2的表达量。结果显示,施予Lipo(M+CpG)-SP,Lipo(M)-CpG-SP纳米疫苗的IFN-γ,TNF-α表达量与施予PBS的阴性对照相比有极显著差异(P<0.001) IL-2的表达量有显著性差别(P<0.05)。IFN-γ的表达量高于铝佐剂组(P<0.05), TNF-α的表达量高于Free(M+CpG+SP)(施予游离SARS-CoV-2S1重组蛋白,游离MPLA,CpG)(P<0.01)和Al+SP组(施予游离SARS-CoV-2S1重组蛋白 +佐剂)(P<0.05)。
图19为用抗原刺激各组小鼠免疫后的CD8+淋巴T细胞内IFN-γ,TNF-α和IL-2的表达量。结果显示,施予Lipo(M+CpG)-SP纳米疫苗的IFN-γ和IL-2 的表达量与施予PBS的阴性对照相比有显著差异(P<0.05),TNF-α的表达量与施予PBS的阴性对照相比有极显著差异(P<0.01)。
实验结果表明,本发明的纳米疫苗对小鼠免疫后,能够增加CD4+和CD8+ 淋巴T细胞IFN-γ,TNF-α和IL-2的表达量,从而增强T细胞介导的细胞免疫效果。
上述实施例为本发明较佳的实施方式,但本发明的实施方式并不受上述实施例的限制,其他的任何未背离本发明的精神实质与原理下所作的改变、修饰、替代、组合、简化,均应为等效的置换方式,都包含在本发明的保护范围之内。
序列表
<110> 中山大学
<120> 一种新型冠状病毒亚单位纳米疫苗的制备和应用
<160> 2
<170> SIPOSequenceListing 1.0
<210> 1
<211> 671
<212> PRT
<213> 新型冠状病毒(SARS-CoV-2)
<400> 1
Val Asn Leu Thr Thr Arg Thr Gln Leu Pro Pro Ala Tyr Thr Asn Ser
1 5 10 15
Phe Thr Arg Gly Val Tyr Tyr Pro Asp Lys Val Phe Arg Ser Ser Val
20 25 30
Leu His Ser Thr Gln Asp Leu Phe Leu Pro Phe Phe Ser Asn Val Thr
35 40 45
Trp Phe His Ala Ile His Val Ser Gly Thr Asn Gly Thr Lys Arg Phe
50 55 60
Asp Asn Pro Val Leu Pro Phe Asn Asp Gly Val Tyr Phe Ala Ser Thr
65 70 75 80
Glu Lys Ser Asn Ile Ile Arg Gly Trp Ile Phe Gly Thr Thr Leu Asp
85 90 95
Ser Lys Thr Gln Ser Leu Leu Ile Val Asn Asn Ala Thr Asn Val Val
100 105 110
Ile Lys Val Cys Glu Phe Gln Phe Cys Asn Asp Pro Phe Leu Gly Val
115 120 125
Tyr Tyr His Lys Asn Asn Lys Ser Trp Met Glu Ser Glu Phe Arg Val
130 135 140
Tyr Ser Ser Ala Asn Asn Cys Thr Phe Glu Tyr Val Ser Gln Pro Phe
145 150 155 160
Leu Met Asp Leu Glu Gly Lys Gln Gly Asn Phe Lys Asn Leu Arg Glu
165 170 175
Phe Val Phe Lys Asn Ile Asp Gly Tyr Phe Lys Ile Tyr Ser Lys His
180 185 190
Thr Pro Ile Asn Leu Val Arg Asp Leu Pro Gln Gly Phe Ser Ala Leu
195 200 205
Glu Pro Leu Val Asp Leu Pro Ile Gly Ile Asn Ile Thr Arg Phe Gln
210 215 220
Thr Leu Leu Ala Leu His Arg Ser Tyr Leu Thr Pro Gly Asp Ser Ser
225 230 235 240
Ser Gly Trp Thr Ala Gly Ala Ala Ala Tyr Tyr Val Gly Tyr Leu Gln
245 250 255
Pro Arg Thr Phe Leu Leu Lys Tyr Asn Glu Asn Gly Thr Ile Thr Asp
260 265 270
Ala Val Asp Cys Ala Leu Asp Pro Leu Ser Glu Thr Lys Cys Thr Leu
275 280 285
Lys Ser Phe Thr Val Glu Lys Gly Ile Tyr Gln Thr Ser Asn Phe Arg
290 295 300
Val Gln Pro Thr Glu Ser Ile Val Arg Phe Pro Asn Ile Thr Asn Leu
305 310 315 320
Cys Pro Phe Gly Glu Val Phe Asn Ala Thr Arg Phe Ala Ser Val Tyr
325 330 335
Ala Trp Asn Arg Lys Arg Ile Ser Asn Cys Val Ala Asp Tyr Ser Val
340 345 350
Leu Tyr Asn Ser Ala Ser Phe Ser Thr Phe Lys Cys Tyr Gly Val Ser
355 360 365
Pro Thr Lys Leu Asn Asp Leu Cys Phe Thr Asn Val Tyr Ala Asp Ser
370 375 380
Phe Val Ile Arg Gly Asp Glu Val Arg Gln Ile Ala Pro Gly Gln Thr
385 390 395 400
Gly Lys Ile Ala Asp Tyr Asn Tyr Lys Leu Pro Asp Asp Phe Thr Gly
405 410 415
Cys Val Ile Ala Trp Asn Ser Asn Asn Leu Asp Ser Lys Val Gly Gly
420 425 430
Asn Tyr Asn Tyr Leu Tyr Arg Leu Phe Arg Lys Ser Asn Leu Lys Pro
435 440 445
Phe Glu Arg Asp Ile Ser Thr Glu Ile Tyr Gln Ala Gly Ser Thr Pro
450 455 460
Cys Asn Gly Val Glu Gly Phe Asn Cys Tyr Phe Pro Leu Gln Ser Tyr
465 470 475 480
Gly Phe Gln Pro Thr Asn Gly Val Gly Tyr Gln Pro Tyr Arg Val Val
485 490 495
Val Leu Ser Phe Glu Leu Leu His Ala Pro Ala Thr Val Cys Gly Pro
500 505 510
Lys Lys Ser Thr Asn Leu Val Lys Asn Lys Cys Val Asn Phe Asn Phe
515 520 525
Asn Gly Leu Thr Gly Thr Gly Val Leu Thr Glu Ser Asn Lys Lys Phe
530 535 540
Leu Pro Phe Gln Gln Phe Gly Arg Asp Ile Ala Asp Thr Thr Asp Ala
545 550 555 560
Val Arg Asp Pro Gln Thr Leu Glu Ile Leu Asp Ile Thr Pro Cys Ser
565 570 575
Phe Gly Gly Val Ser Val Ile Thr Pro Gly Thr Asn Thr Ser Asn Gln
580 585 590
Val Ala Val Leu Tyr Gln Asp Val Asn Cys Thr Glu Val Pro Val Ala
595 600 605
Ile His Ala Asp Gln Leu Thr Pro Thr Trp Arg Val Tyr Ser Thr Gly
610 615 620
Ser Asn Val Phe Gln Thr Arg Ala Gly Cys Leu Ile Gly Ala Glu His
625 630 635 640
Val Asn Asn Ser Tyr Glu Cys Asp Ile Pro Ile Gly Ala Gly Ile Cys
645 650 655
Ala Ser Tyr Gln Thr Gln Thr Asn Ser Pro Arg Arg Ala Arg Ala
660 665 670
<210> 2
<211> 20
<212> DNA
<213> 人工序列(CpG ODN)
<400> 2
tccatgacgt tcctgacgtt 20
Claims (10)
1.一种纳米颗粒,其特征在于,包含SARS-CoV-2病毒棘突蛋白的S1亚基、免疫佐剂、阳离子脂质和辅助脂质。
2.根据权利要求1所述的纳米颗粒,其特征在于,所述纳米颗粒疫苗为脂质体核壳结构,核内为免疫佐剂,壳为包裹在核上的阳离子脂质和辅助脂质,脂质体壳表面负载S1亚基蛋白;或核内为部分免疫佐剂,壳为包裹在核上的阳离子脂质和辅助脂质,颗粒表面负载S1亚基蛋白和另外部分免疫佐剂。
3.根据权利要求1所述的纳米颗粒,其特征在于,所述S1亚基蛋白具有如SEQ ID NO:1所示的氨基酸序列。
4.根据权利要求1所述的纳米颗粒,其特征在于,所述免疫佐剂为单磷脂酰A和/或CpG寡脱氧核苷酸(CpG ODN)。
5.根据权利要求1或4所述的纳米颗粒,其特征在于,所述阳离子脂质为溴化三甲基-2,3-二油酰氧基丙基铵。
6.根据权利要求1或5所述的纳米颗粒,其特征在于,所述辅助脂质为二油酰基磷脂酰乙醇胺和/或胆固醇。
7.根据权利要求6所述的纳米颗粒,其特征在于,所述S1亚基蛋白、单磷脂酰A、CpG寡脱氧核苷酸、溴化三甲基-2,3-二油酰氧基丙基铵、二油酰基磷脂酰乙醇胺和胆固醇的质量比为5~20:0.5~1.5:1~2:150:50:20。
8.权利要求1~5任一项所述的纳米颗粒,其特征在于,所述纳米颗粒的制备包括如下步骤:
S1.提供包含阳离子脂质的溶液、包含辅助脂质的溶液、包含佐剂MPLA的溶液、包含佐剂CpG ODN的溶液和包含SARS-CoV-2S1亚基蛋白的溶液;
S2.将包含阳离子脂质的溶液、包含辅助脂质的溶液、包含佐剂MPLA的溶液混合均匀,除溶剂,获得脂质膜;
S3a.向步骤S2制备得到的脂质膜加入去离子水震荡,超声,过膜得到脂质体;
S4a.将步骤S3a制备得到的脂质体与步骤S1中包含SARS-CoV-2S1亚基蛋白的溶液和包含佐剂CpG ODN的溶液混匀,得到Lipo(M)-CpG-SP颗粒溶液;
或
S3b.向步骤S2制备得到的脂质膜加入包含佐剂CpG ODN的溶液,超声,过膜得到脂质体;
S4b.将步骤S3b制备得到的脂质体与包含SARS-CoV-2S1亚基蛋白的溶液混匀,得到Lipo(M+CpG)-SP颗粒溶液;
S5.对包含纳米颗粒的溶液进行冻干浓缩,得到纳米颗粒。
9.权利要求1~7任一所述纳米颗粒在制备与SARS-CoV-2感染相关疾病的免疫原性组合物中的应用。
10.根据权利要求9所述应用,其特征在于,所述免疫原性组合物还包含药学上可接受的辅料。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010336985.0A CN111603556B (zh) | 2020-04-26 | 2020-04-26 | 一种新型冠状病毒亚单位纳米疫苗的制备和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010336985.0A CN111603556B (zh) | 2020-04-26 | 2020-04-26 | 一种新型冠状病毒亚单位纳米疫苗的制备和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111603556A true CN111603556A (zh) | 2020-09-01 |
CN111603556B CN111603556B (zh) | 2022-05-17 |
Family
ID=72199920
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010336985.0A Active CN111603556B (zh) | 2020-04-26 | 2020-04-26 | 一种新型冠状病毒亚单位纳米疫苗的制备和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111603556B (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112220919A (zh) * | 2020-09-27 | 2021-01-15 | 上海纳米技术及应用国家工程研究中心有限公司 | 以氧化石墨烯为载体的纳米冠状病毒重组疫苗 |
CN113041357A (zh) * | 2021-02-18 | 2021-06-29 | 厦门大学 | 一种针对新型冠状病毒的核酸适体纳米颗粒及其制备方法和应用 |
CN113181355A (zh) * | 2021-04-25 | 2021-07-30 | 大连大学 | 一种DC细胞靶向的纳米SARS-CoV2 S蛋白多肽池疫苗及其制备方法 |
CN113633764A (zh) * | 2021-09-02 | 2021-11-12 | 中国食品药品检定研究院 | 一种含佐剂的新冠dna疫苗 |
WO2022083760A1 (zh) * | 2020-10-23 | 2022-04-28 | 江苏省疾病预防控制中心(江苏省公共卫生研究院) | 融合蛋白及其应用 |
WO2022228560A1 (zh) | 2021-04-30 | 2022-11-03 | 华普生物技术(江苏)股份有限公司 | 人工合成的含CpG单链脱氧寡核苷酸在疫苗中的应用 |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105944098A (zh) * | 2016-06-16 | 2016-09-21 | 安徽医科大学 | 一种基于铝离子的脂质卷载体 |
CN107022008A (zh) * | 2016-01-30 | 2017-08-08 | 复旦大学 | 广谱地抑制人类冠状病毒感染的多肽及其应用 |
CN107583059A (zh) * | 2017-10-31 | 2018-01-16 | 宁夏医科大学 | 一种可包载量子点的阳离子脂质体流感疫苗及其制备方法 |
CN108938593A (zh) * | 2018-07-16 | 2018-12-07 | 中山大学 | 一种脂质包裹固体药物纳米颗粒的制备方法 |
CN109260174A (zh) * | 2018-09-04 | 2019-01-25 | 中山大学 | 一种治疗性蛋白纳米颗粒的高通量制备方法 |
CN109402145A (zh) * | 2018-11-07 | 2019-03-01 | 陕西诺威利华生物科技有限公司 | 一种免疫增强型重组prrsv病毒样颗粒亚单位疫苗的制备方法 |
CN109395073A (zh) * | 2018-11-07 | 2019-03-01 | 陕西诺威利华生物科技有限公司 | 一种免疫增强型重组prrsv病毒样颗粒亚单位疫苗 |
CN110582275A (zh) * | 2017-03-02 | 2019-12-17 | 丹迪生物科技有限公司 | 包含免疫刺激物质的多域囊泡、其制备方法和包含多域囊泡的免疫调节组合物 |
CN110613844A (zh) * | 2019-10-23 | 2019-12-27 | 中国医学科学院生物医学工程研究所 | 一种迷你联合佐剂纳米颗粒及其制备方法和应用 |
CN110638787A (zh) * | 2019-07-31 | 2020-01-03 | 中山大学 | 一种防治鼻咽癌的亚单位纳米疫苗及其制备方法 |
CN110951756A (zh) * | 2020-02-23 | 2020-04-03 | 广州恩宝生物医药科技有限公司 | 表达SARS-CoV-2病毒抗原肽的核酸序列及其应用 |
CN110974950A (zh) * | 2020-03-05 | 2020-04-10 | 广州恩宝生物医药科技有限公司 | 一种用于预防SARS-CoV-2感染的腺病毒载体疫苗 |
-
2020
- 2020-04-26 CN CN202010336985.0A patent/CN111603556B/zh active Active
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107022008A (zh) * | 2016-01-30 | 2017-08-08 | 复旦大学 | 广谱地抑制人类冠状病毒感染的多肽及其应用 |
CN105944098A (zh) * | 2016-06-16 | 2016-09-21 | 安徽医科大学 | 一种基于铝离子的脂质卷载体 |
CN110582275A (zh) * | 2017-03-02 | 2019-12-17 | 丹迪生物科技有限公司 | 包含免疫刺激物质的多域囊泡、其制备方法和包含多域囊泡的免疫调节组合物 |
CN107583059A (zh) * | 2017-10-31 | 2018-01-16 | 宁夏医科大学 | 一种可包载量子点的阳离子脂质体流感疫苗及其制备方法 |
CN108938593A (zh) * | 2018-07-16 | 2018-12-07 | 中山大学 | 一种脂质包裹固体药物纳米颗粒的制备方法 |
CN109260174A (zh) * | 2018-09-04 | 2019-01-25 | 中山大学 | 一种治疗性蛋白纳米颗粒的高通量制备方法 |
CN109402145A (zh) * | 2018-11-07 | 2019-03-01 | 陕西诺威利华生物科技有限公司 | 一种免疫增强型重组prrsv病毒样颗粒亚单位疫苗的制备方法 |
CN109395073A (zh) * | 2018-11-07 | 2019-03-01 | 陕西诺威利华生物科技有限公司 | 一种免疫增强型重组prrsv病毒样颗粒亚单位疫苗 |
CN110638787A (zh) * | 2019-07-31 | 2020-01-03 | 中山大学 | 一种防治鼻咽癌的亚单位纳米疫苗及其制备方法 |
CN110613844A (zh) * | 2019-10-23 | 2019-12-27 | 中国医学科学院生物医学工程研究所 | 一种迷你联合佐剂纳米颗粒及其制备方法和应用 |
CN110951756A (zh) * | 2020-02-23 | 2020-04-03 | 广州恩宝生物医药科技有限公司 | 表达SARS-CoV-2病毒抗原肽的核酸序列及其应用 |
CN110974950A (zh) * | 2020-03-05 | 2020-04-10 | 广州恩宝生物医药科技有限公司 | 一种用于预防SARS-CoV-2感染的腺病毒载体疫苗 |
Non-Patent Citations (4)
Title |
---|
VELJKO VELJKOVIC等: "Use of the informational spectrum methodology for rapid biological analysis of the novel coronavirus 2019-nCoV: prediction of potential receptor, natural reservoir, tropism and therapeutic/vaccine target", 《F1000 RESEARCH》 * |
田靖: "新型冠状病毒疫苗研发的现状与展望", 《生物技术通讯》 * |
许志强等: "新型冠状病毒棘突蛋白免疫原性分析及其多肽疫苗设计研究", 《赣南医学院学报》 * |
陈咏竹等: "刺突蛋白与新型冠状病毒的检测和治疗", 《生物医学工程学杂志》 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112220919A (zh) * | 2020-09-27 | 2021-01-15 | 上海纳米技术及应用国家工程研究中心有限公司 | 以氧化石墨烯为载体的纳米冠状病毒重组疫苗 |
WO2022083760A1 (zh) * | 2020-10-23 | 2022-04-28 | 江苏省疾病预防控制中心(江苏省公共卫生研究院) | 融合蛋白及其应用 |
CN113041357A (zh) * | 2021-02-18 | 2021-06-29 | 厦门大学 | 一种针对新型冠状病毒的核酸适体纳米颗粒及其制备方法和应用 |
CN113181355A (zh) * | 2021-04-25 | 2021-07-30 | 大连大学 | 一种DC细胞靶向的纳米SARS-CoV2 S蛋白多肽池疫苗及其制备方法 |
WO2022228560A1 (zh) | 2021-04-30 | 2022-11-03 | 华普生物技术(江苏)股份有限公司 | 人工合成的含CpG单链脱氧寡核苷酸在疫苗中的应用 |
CN113633764A (zh) * | 2021-09-02 | 2021-11-12 | 中国食品药品检定研究院 | 一种含佐剂的新冠dna疫苗 |
CN113633764B (zh) * | 2021-09-02 | 2024-05-14 | 中国食品药品检定研究院 | 一种含佐剂的新冠dna疫苗 |
Also Published As
Publication number | Publication date |
---|---|
CN111603556B (zh) | 2022-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111603556B (zh) | 一种新型冠状病毒亚单位纳米疫苗的制备和应用 | |
KR102399854B1 (ko) | 면역원성 중동호흡기증후군 코로나바이러스 (ΜERS-CoV) 조성물 및 방법 | |
JP3980884B2 (ja) | プロテオソーム・インフルエンザ・ワクチン | |
WO2021155760A1 (zh) | 用于2019-nCoV型冠状病毒mRNA疫苗、制备方法及其应用 | |
Wang et al. | Double‐Layered M2e‐NA Protein Nanoparticle Immunization Induces Broad Cross‐Protection against Different Influenza Viruses in Mice | |
KR20090079912A (ko) | 노로바이러스 백신 제제 | |
KR101225199B1 (ko) | 항원보강제를 함유하는 기능적으로 재구성된 바이러스막 | |
US10245319B2 (en) | Lymph node-targeting nanoparticles | |
Lopez-Cantu et al. | From bench to the clinic: the path to translation of nanotechnology-enabled mRNA SARS-CoV-2 vaccines | |
CN108697786B (zh) | 含有固定化病毒粒子的疫苗 | |
CN101048498B (zh) | 包含来自流感病毒和乙型肝炎病毒的抗原的病毒体颗粒 | |
CN115444931A (zh) | 均衡诱导抗病毒细胞与体液免疫的核酸-纳米乳的构建与应用 | |
Lin et al. | Nanoparticular CpG-adjuvanted SARS-CoV-2 S1 protein elicits broadly neutralizing and Th1-biased immunoreactivity in mice | |
EP3333178A1 (en) | Recombinant hemagglutinin protein of influenza virus and vaccine containing the same | |
Wang et al. | Monophosphoryl lipid A-adjuvanted nucleoprotein-neuraminidase nanoparticles improve immune protection against divergent influenza viruses | |
US9060984B2 (en) | Recombinant HIV-1 envelope proteins comprising stabilizing two-cysteine mini-domains in gp41 | |
CN111840538A (zh) | 一种水痘-带状疱疹病毒亚单位纳米疫苗的制备方法和应用 | |
Zhang et al. | Nanomedicine approaches against SARS-CoV-2 and variants | |
Rosales-Mendoza et al. | RNA-based vaccines against SARS-CoV-2 | |
CN101754770A (zh) | 皮内流感疫苗 | |
EP1802746A2 (en) | Virosome particles comprising antigens from influenza virus and hepatitis b virus | |
WO2024041612A1 (zh) | 一种正痘病毒属mRNA疫苗及其制备方法和用途 | |
CN111729082B (zh) | 一种流感亚单位疫苗及其制备方法 | |
JPWO2013011942A1 (ja) | 変異狂犬病ウイルス及びワクチン | |
CN101405027B (zh) | 基于病毒颗粒的鼻内流感疫苗 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |